HSV-1 mutants in the RL-1 gene encoding the ICP34.5 protein have been
demonstrated to have diminished neurovirulence in brain yet replicate
as efficiently as parental virus in transformed tissue culture cells.
Thus they have been proposed as candidates viruses for human brain tum
or therapies, Evaluation of their replicative properties and pathogene
sis within the nervous system has been limited, As most patients under
going therapies for brain tumors are likely to be immunocompromised, i
t will be important to understand the pathogenesis of these viruses in
immunocompromised hosts, To this end, the lateral ventricle of nude m
ice was injected with high (2.5 x 10(7) PFU), medium (10(5) PFU), or l
ow dose (10(3) PFU) HSV-1 variant-1716, which has a deletion in the RL
-1 gene, Ten of 10 mice died within 2 - 3 days following the high tite
r infection, Six of 19 animals with medium titer infection died within
9 days, and viral antigens were seen in ependymal cells as well as ne
urons within the brainstem and thalamus. Although only two of 19 anima
ls became moribund 18 days after medium alter viral infection, many ne
ocortical and hippocampal neurons were positive for HSV-1 antigens. Ho
wever, plaque-purified viral isolates recovered from brain homogenates
of these animals demonstrated no increase in pathogenicity. Nine of 2
0 animals died following low dose infection; six of these animals, fro
m which tissue was analyzed, all had many RSV antigen-positive neurons
in the neocortex and hippocampus. These data imply that if this type
of virus is used for human brain tumor therapy immunosuppressed patien
ts may suffer from significant viral pathogenesis outside the tumor.